Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 24
1988 3
1989 3
1990 7
1991 3
1992 6
1993 1
1994 8
1995 6
1996 8
1997 15
1998 5
1999 4
2000 2
2001 3
2002 6
2003 1
2004 6
2005 1
2006 2
2007 1
2008 4
2009 1
2010 2
2012 3
2013 1
2018 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
N,N´-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl-3-methoxypropyl)-acetamidol]-2,4,6-triiodoisophthalamide.
Cheng KT. Cheng KT. 2006 Mar 6 [updated 2008 Mar 4]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2006 Mar 6 [updated 2008 Mar 4]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641971 Free Books & Documents. Review.
N,N-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl-3-methoxypropyl)-acetamidol]-2,4,6-triiodoisophthalamide (iopentol) is a nonionic X-ray contrast agent used in various radiologic procedures to aid the radiographic visualization of selected tissues or organs. ...Further im …
N,N-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl-3-methoxypropyl)-acetamidol]-2,4,6-triiodoisophthalamide (iopentol) is a nonionic X …
Iopentol in patients with chronic renal failure: its effects on renal function and its use as glomerular filtration rate parameter.
Berg KJ, Kolmannskog F, Lillevold PE, Nordal KP, Ressem L, Rootwelt K, Svaland MG. Berg KJ, et al. Scand J Clin Lab Invest. 1992 Feb;52(1):27-33. doi: 10.3109/00365519209085437. Scand J Clin Lab Invest. 1992. PMID: 1594886
The elimination of iopentol from serum and urine was delayed, and detectable serum and urine concentrations were found 5 days after administration of the contrast medium. Creatine clearance was 47% higher than the corresponding renal iopentol clearance. Plasma io …
The elimination of iopentol from serum and urine was delayed, and detectable serum and urine concentrations were found 5 days after a …
Iopentol (Imagopaque 350) compared with iohexol (Omnipaque 350) in pediatric cardioangiography. A clinical trial assessing adverse events, ECG, blood pressure and diagnostic information.
Kunnen M, De Greef D, Skinningsrud K. Kunnen M, et al. Eur Radiol. 1997;7 Suppl 4:S123-6. doi: 10.1007/pl00006877. Eur Radiol. 1997. PMID: 9204353 Clinical Trial.
The aims of the study were to compare the safety and radiographic efficacy of iopentol 350 mg I/ml versus those of iohexol 350 mg I/ ml in pediatric cardioangiography. ...Iopentol was demonstrated to be as effective, safe and well tolerated as iohexol in pediatric c …
The aims of the study were to compare the safety and radiographic efficacy of iopentol 350 mg I/ml versus those of iohexol 350 mg I/ …
Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in abdominal CT. A multi-centre monitoring trial assessing adverse events and diagnostic information--results from 518 patients in Spain.
Encina JL, Martí-Bonmatí L, Ronchera-Oms CL, Rodríguez V. Encina JL, et al. Eur Radiol. 1997;7 Suppl 4:S115-9. doi: 10.1007/pl00006875. Eur Radiol. 1997. PMID: 9204351 Clinical Trial.
OBJECTIVES: Iopentol (Nycomed Imaging AS, Oslo, Norway) and iopromide (Schering AG, Berlin, Germany) are low-osmolar, non-ionic, iodinated contrast media (CM) used in abdominal CT examinations. ...MATERIALS AND METHODS: A prospective, double-blind, randomized, multicentre, …
OBJECTIVES: Iopentol (Nycomed Imaging AS, Oslo, Norway) and iopromide (Schering AG, Berlin, Germany) are low-osmolar, non-ionic, iodi …
A double-blind CT study comparing the safety and efficacy of iopentol and ioxaglate in paediatric patients.
Sayegh N, Porée C, Baraton J, Skinningsrud K, Nantois C, Lallemand D. Sayegh N, et al. Eur Radiol. 1996;6(4):574-7. doi: 10.1007/BF00182498. Eur Radiol. 1996. PMID: 8798046 Clinical Trial.
There was a total of 18 patients who reported adverse events other than sensations of heat or cold, 6 (13%) in the iopentol group and 12 (27%) in the ioxaglate group. Two patients (4%) in the iopentol group reported possible contrast-related events as described abov …
There was a total of 18 patients who reported adverse events other than sensations of heat or cold, 6 (13%) in the iopentol group and …
Pharmacokinetics of iopentol in healthy volunteers.
Waaler A, Jørgensen NP, Koksvik B, Skinnemoen K, Andrew E. Waaler A, et al. Acta Radiol Suppl. 1987;370:113-7. Acta Radiol Suppl. 1987. PMID: 2980304
Iopentol is a new non-ionic contrast medium. In order to study the pharmacokinetic properties, iopentol 350 mg I/ml was administered intravenously to healthy male volunteers at 3 dose levels (0.3, 0.6 and 1.2 g I/kg body weight). To evaluate renal excretion all subj …
Iopentol is a new non-ionic contrast medium. In order to study the pharmacokinetic properties, iopentol 350 mg I/ml was admini …
Assessing the effectiveness of X-ray contrast media for abdominal computed tomographic examinations: comparison of four low-osmolality agents.
Martí-Bonmatí L, Ronchera-Oms CL, Espinós MA, Jordán Y, Lucas A. Martí-Bonmatí L, et al. J Clin Pharm Ther. 1995 Apr;20(2):75-81. doi: 10.1111/j.1365-2710.1995.tb00632.x. J Clin Pharm Ther. 1995. PMID: 7650078 Clinical Trial.
Hepatic peak values were attained earlier for iopromide, although these were lower than those produced by any other of the agents evaluated in this study. Iopentol produced fast and intense hepatic peaks. Consequently, high AUC values were obtained with iopentol, lo …
Hepatic peak values were attained earlier for iopromide, although these were lower than those produced by any other of the agents evaluated …
Iopentol (Imagopaque 350) compared with diatrizoate (Urografin 370) in cerebral CT. A clinical trial assessing immediate and late (7 days) adverse events and diagnostic information (visualization quality and Hounsfield unit measurements).
Valentine A, Jakobsen JA, Klaveness AJ. Valentine A, et al. Eur Radiol. 1997;7 Suppl 4:S145-8. doi: 10.1007/pl00006882. Eur Radiol. 1997. PMID: 9204358 Clinical Trial.
Delayed adverse events were also significantly less frequent in the iopentol group (43%) than in the diatrizoate group (69%), p = 0.047. Patients in the iopentol group reported significantly less discomfort (53%), especially sensation of warmth, than patients in the …
Delayed adverse events were also significantly less frequent in the iopentol group (43%) than in the diatrizoate group (69%), p = 0.0 …
Iopentol (Imagopaque 300 and 350) compared with iohexol (Omnipaque 300 and 350) in cerebral and aortic arch angiography. A clinical trial assessing adverse events and diagnostic information.
Ericsson K, Bjartveit K. Ericsson K, et al. Eur Radiol. 1997;7 Suppl 4:S152-5. doi: 10.1007/pl00006884. Eur Radiol. 1997. PMID: 9204360 Clinical Trial.
The safety of the non-ionic contrast medium iopentol (Imagopaque, Nycomed Imaging AS, Oslo, Norway) when used in cerebral angiography and aortic arch angiography, was the focus of this investigation. ...A sensation of heat was reported by 21 patients (54%) in the iopent …
The safety of the non-ionic contrast medium iopentol (Imagopaque, Nycomed Imaging AS, Oslo, Norway) when used in cerebral angiography …
124 results